Lansoford Junior 15mg Tablet DT contains Lansoprazole 15mg, a proton pump inhibitor indicated for the treatment of acid-related gastrointestinal conditions in pediatric patients. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This formulation is designed as a dispersible tablet, facilitating ease of administration and improved compliance in children who may have difficulty swallowing conventional tablets. Lansoford Junior is primarily prescribed for the management of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-mediated disorders in children aged 1 to 11 years. The medication provides symptomatic relief from heartburn, regurgitation, and esophageal inflammation by reducing gastric acidity, promoting mucosal healing. It is generally well tolerated; however, adverse effects may include headache, abdominal pain, diarrhea, or nausea. Lansoford Junior should be administered as directed by a healthcare professional, typically once daily before meals. Caution is advised in patients with known hypersensitivity to Lansoprazole or other proton pump inhibitors. Regular monitoring and adherence to prescribed dosage are essential to ensure therapeutic efficacy and minimize potential side effects. Lansoford Junior 15mg Tablet DT represents a safe and effective option for pediatric acid suppression therapy.